Phase 4 Hypertension Trial, Recruiting NCT06676553 Sponsor: National Taiwan University Hospital Condition: Hypertension
Back to Hypertension

Phase 4 Hypertension Trial, Recruiting

NCT06676553
Recruiting Phase 4

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have high blood pressure (hypertension) and are willing to undergo a procedure called renal denervation, which targets the nerves around the kidneys to help lower blood pressure.
  • People who are either taking medication to manage their blood pressure, or whose blood pressure readings are above certain levels — specifically, an office reading above 140/90 mmHg and a 24-hour reading above 130/80 mmHg — regardless of whether they are on blood pressure medication.

Who may not be able to join:

  • People whose kidney arteries are not suitable for the renal denervation procedure — for example, if the artery is too narrow (less than 3mm wide) or too short (less than 20mm long), as determined by a special type of scan called a CT angiography.
  • People whose high blood pressure is caused by another medical condition, such as a hormone-producing tumour (pheochromocytoma), overproduction of a hormone called aldosterone (hyperaldosteronism), or a significant narrowing (more than 50%) in one or both kidney arteries.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.

Contact this trial

Principal Investigator: Tzung-Dau Wang, MD, PhD, National Taiwan University Hospital

Phone: 886-972651070

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 4
Registry
ClinicalTrials.gov
Start date
14 October 2024
Est. completion
31 October 2026

Where this trial is recruiting

🇹🇼 Taiwan

Primary endpoints

24-hour systolic blood pressure reduction (compared to baseline)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov